Allison Talbot 11/3/25 Allison Talbot 11/3/25 PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Read More Allison Talbot 1/9/25 Allison Talbot 1/9/25 PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) Read More Allison Talbot 4/11/24 Allison Talbot 4/11/24 PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers Read More Allison Talbot 3/13/24 Allison Talbot 3/13/24 PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia Read More
Allison Talbot 11/3/25 Allison Talbot 11/3/25 PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Read More
Allison Talbot 1/9/25 Allison Talbot 1/9/25 PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) Read More
Allison Talbot 4/11/24 Allison Talbot 4/11/24 PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers Read More
Allison Talbot 3/13/24 Allison Talbot 3/13/24 PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia Read More
